# DESCRIPTION

## FIELD

- relate to polypeptides and methods

## BACKGROUND

- describe NiV and its effects

## SUMMARY

- introduce recombinant NiV F ectodomain trimers
- describe prefusion-stabilized NiV F ectodomain trimers
- describe amino acid substitutions
- describe trimerization domains and fusion proteins
- describe immunogenic compositions and methods

## SEQUENCES

- list nucleic and amino acid sequences
- describe SEQ ID NO: 1-52
- describe SEQ ID NO: 53-65
- describe SEQ ID NO: 66-68
- describe SEQ ID NO: 69-70

## DETAILED DESCRIPTION

- disclose recombinant NiV F ectodomain trimers

### I. Summary of Terms

- define technical terms
- explain usage of singular and plural forms
- define "comprises"
- explain approximate values for base sizes and molecular weights
- describe adjuvants
- define administration
- explain amino acid substitution
- define antibody
- describe carrier
- explain cavity-filling amino acid substitution
- define conservative variants
- describe control
- explain degenerate variant
- define effective amount
- explain expression
- describe expression control sequences
- define expression vector
- explain GCN4 trimerization domain
- define heterologous, host cells, immune response, immunogen, immunogenic composition, inhibiting or treating a disease, and isolated
- define native protein, sequence, or disulfide bond
- define Nipah Virus (NiV)
- describe NiV genome
- describe NiV infection in humans
- define NiV attachment glycoprotein (G)
- provide NiV G protein sequence
- define NiV fusion (F) protein
- describe NiV F protein structure
- define NiV F prefusion specific antibody
- define nucleic acid molecule
- define operably linked
- describe pharmaceutically acceptable carriers
- define polypeptide
- describe prime-boost vaccination
- define protein nanoparticle
- define recombinant
- describe sequence identity
- define signal peptide
- define specifically bind
- define soluble protein
- define subject
- describe T4 fibritin trimerization domain
- define transmembrane domain
- define vaccine

### II. Immunogens

- introduce recombinant NiV F ectodomain trimers
- describe stabilization in prefusion conformation
- list embodiments with cysteine substitutions
- list embodiments with proline substitutions
- list embodiments with phenylalanine substitutions
- list embodiments with glycine substitutions
- list embodiments with combinations of substitutions
- describe elimination of protease cleavage site
- provide non-limiting examples of specific amino acid substitutions
- describe additional amino acid substitutions
- describe modifications to membrane proximal portion
- describe N-terminal and C-terminal positions of protomers
- provide examples of protomers with trimerization domains
- describe membrane anchoring of recombinant NiV F ectodomain trimer
- introduce NiV F ectodomain trimers
- link to heterologous moiety
- fuse to NiV G ectodomain
- fuse to ectodomain of G protein from henipavirus
- describe NiV G multimers including trimerization domain
- provide additional description of modifications
- describe amino acid substitutions
- describe joining to unrelated sequences
- describe solubility in aqueous solution
- describe homogenous population of soluble trimers
- describe retention of specific binding for prefusion specific antibody
- describe modification with nonproteinaceous moieties
- describe removal of sequences for therapeutic use
- define protein nanoparticles
- describe ferritin nanoparticles
- provide examples of ferritin subunits
- describe lumazine synthase nanoparticles
- provide examples of lumazine synthase subunits
- describe encapsulin nanoparticles
- provide examples of encapsulin subunits
- describe Sulfur Oxygenase Reductase (SOR) nanoparticles
- describe production and purification of protein nanoparticles

### II. Polynucleotides and Expression

- provide polynucleotides encoding immunogens
- describe nucleic acid sequences encoding protomers of NiV F ectodomain trimer
- discuss expression of polynucleotides in host cells
- describe transformation of host cells with recombinant DNA
- outline methods of expressing DNA sequences in cells
- discuss modifications to nucleic acids encoding immunogens
- describe expression of immunogens in cells under conditions for self-assembly into trimers
- discuss purification of recombinant NiV F ectodomain trimer from cell media

### III. Viral Vectors

- describe inclusion of nucleic acid molecules in viral vectors
- discuss use of viral vectors for expression of immunogens in host cells
- outline examples of viral vectors for expression of disclosed antigens

### IV. Virus-Like Particles

- describe virus-like particles including immunogens

### V. Immunogenic Compositions

- provide immunogenic compositions comprising disclosed immunogens
- discuss formulation of immunogenic compositions with pharmaceutically acceptable carriers
- describe optional inclusion of adjuvants in immunogenic compositions
- outline examples of adjuvants for use in immunogenic compositions
- discuss administration of immunogenic compositions to subjects
- describe combination of disclosed immunogens with other pharmaceutical products

### VI. Methods of Inducing an Immune Response

- administer immunogen to induce immune response
- select subject for treatment based on risk factors
- monitor subject for NiV infection or symptoms
- identify subjects for prophylaxis or treatment using screening methods
- administer immunogen for prophylactic or therapeutic purpose
- provide immunogen prior to exposure to NiV
- provide immunogen after exposure to NiV
- elicit production of immune response against NiV
- determine dosage of immunogen based on factors
- use coordinate vaccination protocols or combinatorial formulations
- administer prime and boost in single or multiple doses
- determine adequacy of vaccination parameters
- monitor clinical condition of subject for desired effect
- modify vaccination parameters to potentiate immune response
- use DNA-primer and protein-boost vaccination protocol
- determine effective dosages using animal model studies or in vitro models
- administer immunogenic composition to reduce or prevent NiV infection

## EXAMPLES

- introduce examples of certain embodiments

### Example 1

- stabilize NiV F proteins in prefusion conformation
- describe mutations for stabilization
- express and purify mutants
- assess binding to prefusion NiV F antibody
- combine mutations for prefusion stabilization and protein production
- express and purify combined mutants
- assess binding to prefusion-stabilized NiV F ectodomain trimer
- conduct immunization assays
- assess neutralization titer of sera from immunized mice
- test sera for binding to prefusion-stabilized NiV F ectodomain trimer
- assess immune sera in NiV neutralization assay
- summarize methods

### Example 2

- describe NiV G multimers
- express and purify multimers
- conduct immunization assays

### Example 3

- describe multimers of NiV F-G ectodomain chimeras
- express, purify, and assess multimers

### Example 4

- describe immunization protocol
- present immunization results
- show neutralization correlation

### Example 5

- report thermal stability assays

### Example 6

- compare immunogen variations

### Example 7

- describe mouse model immunization

